RNA & DNA Modifications

Pseudouridine (Ψ), often referred to as the “fifth nucleotide,” is one of the most abundant and widespread RNA modifications. It arises through the isomerization of uridine, where the bond linking the base to the sugar shifts from a nitrogen–carbon to a carbon–carbon linkage. This subtle structural rearrangement enhances base stacking and stabilizes local RNA architecture, making pseudouridine crucial for the proper function of tRNA and rRNA.

In messenger RNA, pseudouridine modulates transcript stability, influences splicing patterns, and affects translation dynamics. The biological importance of Ψ has gained widespread attention due to its role in synthetic mRNA technology, where pseudouridine incorporation minimizes innate immune activation and increases protein production—features central to the success of mRNA vaccines. Pseudouridylation is catalyzed by pseudoruridine synthases (PUS enzymes) or guided by H/ACA box small nucleolar RNAs, and defects in these pathways are increasingly linked to neurological disorders and immune dysregulation.

Acetylation of cytidine, resulting in the formation of N4-acetylcytidine (ac4C), is a conserved modification found in tRNA, rRNA, and mRNA. This modification is primarily catalyzed by the enzyme NAT10, which transfers an acetyl group to specific cytidine residues. The presence of ac4C enhances RNA stability by protecting transcripts from degradation and improves the accuracy and efficiency of translation by promoting proper codon–anticodon pairing in tRNAs and structural stability in rRNAs. In mRNA, ac4C appears to support efficient translation initiation and may serve as a regulatory marker during cellular stress. Dysregulation of ac4C-modifying enzymes has been linked to cancer progression, viral infection, and metabolic disturbances, highlighting the modification’s relevance in human health and disease.

Nucleic acid glycosylation is an emerging and relatively understudied area compared to other RNA and DNA modifications, but recent discoveries suggest it may play significant regulatory roles. Glycosylation involves the covalent addition of sugar moieties to nucleic acids, a modification once thought to be exclusive to proteins and lipids. In DNA, these sugar attachments may influence interactions with chromatin-associated proteins, potentially affecting transcriptional accessibility or DNA repair mechanisms.

In RNA, glycosylation may impact folding dynamics, intracellular transport, and recognition by specific binding proteins or immune receptors. Some studies suggest that glycosylated RNA may function at the interface of cellular communication and host–pathogen interactions, providing signals that help distinguish between self and foreign nucleic acids. Although research in this field is still evolving, nucleic acid glycosylation is increasingly recognized as a potentially important mechanism in epigenetic and epitranscriptomic regulation.

Adenosine-to-Inosine (A-to-I) editing is a post-transcriptional modification in which specific adenosine residues are deaminated to inosine by enzymes known as ADARs (adenosine deaminase acting on RNA). Because inosine is interpreted as guanosine during translation and base pairing, this modification can effectively recode RNA sequences, altering codons, modifying splice sites, and reshaping RNA secondary structures. A-to-I editing thus significantly expands transcriptomic and proteomic diversity without altering the underlying DNA template.

Beyond its role in protein diversification, A-to-I editing is essential for preventing aberrant immune activation. Double-stranded RNA structures generated during normal transcription can resemble viral dsRNA, and ADAR enzymes modify these structures to signal that they originate from the host. When A-to-I editing is impaired, these endogenous RNAs can trigger innate immune pathways, contributing to autoimmune and inflammatory diseases. Dysregulated editing has also been implicated in cancer, neurological disorders, and viral infections, making ADAR activity a growing area of therapeutic interest.